brain cancer

Much like Dendreon, which has a promising prostate cancer drug, ImmunoCellular is developing a cancer drug. In this case, it battles brain cancer, and a Phase I trial turned in remarkable results. But unlike Dendreon, ImmunoCellular is still pretty much an unknown.

Shares of Celldex Therapeutics dove over 30% Friday after Pfizer abandoned its partnership with the small biotech to develop a brain cancer vaccine. Celldex says it will continue to develop the treatment alone.